Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of AK130 combined with AK112 in advanced pancreatic cancer
CTR20253246Phase 2Active
- Sponsor
- Akeso, Inc.
- Start
- Sep 2025
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes, Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of lucorafusp alfa, ivonescimab in pancreatic adenocarcinoma (PDAC), sponsored by Akeso, Inc.. Started Sep 2025; status: active.
02
Drugs
lucorafusp alfaivonescimab
03
Conditions
pancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on CTR20253246.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20253246.